FLT3 and acute myeloid leukemia: Therefore, the current standard of care for AML children with FLT3‐ITD mutation is intensive chemotherapy plus a tyrosine kinase inhibitors (TKI), such as sorafenib, midostaurin, or quizartinib, followed by HSCT.26